June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726–1737 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021).

Article  CAS  PubMed  Google Scholar 

Choi, B. D. et al. Intraventricular CARv3-TEAM-E T Cells in recurrent glioblastoma. N. Engl. J. Med. 390, 1290–1298 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Müller, F. et al. CD19 CAR T-cell therapy in autoimmune disease — a case series with follow-up. N. Engl. J. Med. 390, 687–700 (2024).

Article  PubMed  Google Scholar 

Rejeski, K. et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. J. Immunother. Cancer 10, e004475 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45–56 (2019).

Article  CAS  PubMed  Google Scholar 

Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839–852 (2020).

Article  PubMed  Google Scholar 

Karschnia, P. et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood 133, 2212–2221 (2019).

Article  CAS  PubMed  Google Scholar 

Gudera, J. A., Baehring, J. M. & Karschnia, P. Parkinsonism following chimeric antigen receptor T cell therapy. JAMA Neurol. 81, 1223–1224 (2024).

Article  Google Scholar 

Karschnia, P. et al. Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells. Neuro Oncol. 25, 2239–2249 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25, 625–638 (2019).

Article  CAS  Google Scholar 

Graham, C. E. et al. Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee. Lancet Oncol. 26, e203–e213 (2025).

Article  CAS  PubMed  Google Scholar 

Karschnia, P. et al. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood 142, 1243–1248 (2023).

Article  CAS  PubMed  Google Scholar 

Bagley, S. J. et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results. Nat. Med. 30, 1320–1329 (2024).

Article  CAS  PubMed  Google Scholar 

Shah, N. N. et al. CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J. Clin. Oncol. 38, 1938–1950 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bachy, E. et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat. Med. 28, 2145–2154 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Furqan, F. et al. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 8, 4320–4329 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grant, S. J. et al. Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review. Transpl. Cell Ther. 28, 294–302 (2022).

Article  CAS  Google Scholar 

First-ever CAR T-cell therapy approved in U.S. Cancer Discov. 7, OF1 (2017).

Gust, J., Ponce, R., Liles, W. C., Garden, G. A. & Turtle, C. J. Cytokines in CAR T cell-associated neurotoxicity. Front. Immunol. 11, 577027 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Santomasso, B. D. et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 8, 958–971 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parker, K. R. et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 183, 126–142.e17 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karschnia, P. et al. Clinicopathologic findings in fatal neurotoxicity after adoptive immunotherapy with CD19-directed CAR T-cells. Hemasphere 5, e533 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Berger, S. C. et al. Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy. Haematologica 108, 444–456 (2023).

Article  CAS  PubMed  Google Scholar 

Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739–748 (2018).

Article  CAS  PubMed  Google Scholar 

Vinnakota, J. M. et al. Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome. Nat. Cancer 5, 1227–1249 (2024).

Article  CAS  PubMed  Google Scholar 

Schoeberl, F. et al. Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment. Blood Adv. 6, 3022–3026 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Butt, O. H. et al. Assessment of pretreatment and posttreatment evolution of neurofilament light chain levels in patients who develop immune effector cell-associated neurotoxicity syndrome. JAMA Oncol. 8, 1652–1657 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Ursu, R. et al. Long-term neurological safety in B-cell lymphoma patients treated with anti-CD19 CAR T-cell therapy. Neurology 99, 511–515 (2022).